Wang, Yi-Ching National Cheng Kung University, Tainan, Taiwan Genomic study: Genome-wide deletion analysis enables the delineation of the likely locations of tumor suppressor genes (TSG) and could provide molecular markers for disease classification. To define the minimal deletion regions (MDRs) in lung cancer, we used 92 microsatellite markers spanning 29 regions in 36 lung squamous cell carcinoma (SCC) patients designed to verify the maximal contiguous deletion loci. Eight MDRs were found. The candidate genes GAS7 and OVCA2 in the MDR17pA (17p13.1-p13.2) were further examined for mRNA expression. Low expression of the GAS7 gene in 57% of patients analyzed suggested its importance in lung SCC tumorigenesis. In addition, we found a panel of five microsatellites, which can be used as prognostic biomarkers in lung cancer. Furthermore, alteration in more than two genes in the p53 damage response gene and in the double-strand break (DSB) repair genes, BRCA1 and XRCC5 was more apparent in high chromosome instability patients showing as high fractional allelic loss (FAL) than in low FAL patients. Our results provide biomarkers that may be used for monitoring tumor progression and for positional cloning of new TSGs. Our data show direct evidence that alterations in DSB repair and damage response pathways is involved in the genomic instability verified by intensive microsatellites of lung cancer. Epigenomic study: We established a genome-wide hypermethylation analysis using the microarray-based strategy called differential methylation hybridization (DMH) containing ~8,000 CpG islands to identify the regions of hypermethylation in 30 lung cancer patients. The genes located in these methylated regions were further identified by the BLAST method. Common methylated genes at the stage-specific manner were identified. Several genes were specifically associated with adenocarcinoma or squamous lung cancer patients, which are two major subtypes of lung cancer. These methylated genes were further confirmed for their low mRNA expression in 20 patients. Overexpression of DNA 5'-cytosine-methyltransferase 1 (DNMT1) has been reported in various cancers. However, the mechanism underlying overexpression of DNMT1 and to the "methylator" phenotype we observed Copyright © 2007 by the International Association for the Study of Lung Cancer S378 remains unclear. We performed DNMT1 promoter luciferase assay and found that wild type p53 could negatively regulate the DNMT1 promoter, whereas mutant p53 could activate DNMT1 promoter activity. The physical binding of wild type p53 and mutant p53 to DNMT1 promoters was identified by chromatin immunoprecipitation. These data suggest that deregulation of DNMTs is associated with the loss of transcriptional repression of p53. The p53 mutation results in overexpression of DNMT1 and hypermethyaltion of target tumor suppressor genes and ultimately leads to tumorigenesis.
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Gene expression signatures associated with lung adenocarcinomas in female non-smoker Chinese patients
Lam Methods: NSCLC tumor specimens (n = 167) with adenocarcinoma (n = 161) and adenosquamous carcinoma histologies (n = 6) were collected from surgical resections and RNA was extracted using routine methods. Some of the specimens (n = 63) were collected in Korea, while rest of the specimens (n = 104) came from Caucasian patients from the US. Tumors were screened for LKB1 mutations using the SURVEYOR-WAVE method. In SURVEYOR-WAVE method, the whole coding region of LKB1 gene was PCR amplified in two overlapping amplicons, PCR products were digested with SURVEYOR-enzyme which cleaves mismatches, and the specimens were analyzed with sensitive HPLC method for shorter digestion products. If digestion products were present, the specimen was sequenced using Sanger method to verify the mutation. Mutational analysis K-Ras, B-Raf, and EGFR hotpots were done either by SURVEYOR-WAVE method analogously to LKB1 gene analysis or by direct sequencing with Sanger method. Statistical comparisons were done using Fisher's exact test, p values < 0.05 were considered significant Results: Mutations of the LKB1 gene were detected in twenty-two tumors (13%). Interestingly, twenty of the LKB1 mutations were detected in specimens collected in U.S. (prevalence 19%) while only two mutations (prevalence 3%) were detected in specimens from Asian origin (p = 0.004). The mutations were mainly deletions and insertions (82%) but some missense (9%), and nonsense (9%) mutations were also found. No correlation of LKB1 mutations to gender, age, or stage
